Atara Biotherapeutics Inc ATRA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$9.18 down $0.47, 4.87% at close Oct 16
Last close · Previous close $9.65
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.29Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$9.18down $0.93, 9.20%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$9.65Oct 15
- Volume19.49KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume36.46KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.92 to $19.15; now $9.18
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ATRA beat the S&P 500 in 1 of 7 periods.
| Period | ATRA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ATRA: down 9.2% S&P 500: up 1.5% | ATRA trailed the S&P 500 by 10.7 percentage points Trailed |
| 3M | ATRA: up 5.3% S&P 500: up 1.9% | ATRA beat the S&P 500 by 3.4 percentage points Beat |
| YTD | ATRA: down 49.3% S&P 500: up 12.8% | ATRA trailed the S&P 500 by 62.1 percentage points Trailed |
| 1Y | ATRA: down 39.8% S&P 500: up 16.8% | ATRA trailed the S&P 500 by 56.6 percentage points Trailed |
| Long term | ||
| 3Y | ATRA: down 76.5% S&P 500: up 81.5% −38.3% vs +22.0% a year | ATRA trailed the S&P 500 by 158.0 percentage points Trailed |
| 5Y | ATRA: down 97.6% S&P 500: up 83.1% −52.5% vs +12.9% a year | ATRA trailed the S&P 500 by 180.7 percentage points Trailed |
| 10Y | ATRA: down 97.7% S&P 500: up 319.6% −31.5% vs +15.4% a year | ATRA trailed the S&P 500 by 417.3 percentage points Trailed |
$10,000 invested in ATRA 10 years ago (Oct 14, 2016) would be worth about $229 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
ATRA beat the S&P 500 in 1 of 7 periods.
| Period | ATRA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ATRA: down 9.2% S&P 500: up 1.2% | ATRA trailed the S&P 500 by 10.4 percentage points Trailed |
| 3M | ATRA: up 5.3% S&P 500: up 1.7% | ATRA beat the S&P 500 by 3.6 percentage points Beat |
| YTD | ATRA: down 49.3% S&P 500: up 11.9% | ATRA trailed the S&P 500 by 61.2 percentage points Trailed |
| 1Y | ATRA: down 39.8% S&P 500: up 15.5% | ATRA trailed the S&P 500 by 55.3 percentage points Trailed |
| Long term | ||
| 3Y | ATRA: down 76.5% S&P 500: up 75.0% −38.3% vs +20.5% a year | ATRA trailed the S&P 500 by 151.5 percentage points Trailed |
| 5Y | ATRA: down 97.6% S&P 500: up 71.2% −52.5% vs +11.4% a year | ATRA trailed the S&P 500 by 168.8 percentage points Trailed |
| 10Y | ATRA: down 97.7% S&P 500: up 258.1% −31.5% vs +13.6% a year | ATRA trailed the S&P 500 by 355.8 percentage points Trailed |
$10,000 invested in ATRA 10 years ago (Oct 14, 2016) would be worth about $229 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$1,600.50
Closing high on . Now 99.4% below that record.
Split-adjusted daily closes since Oct 16, 2014.
Stock splits
1
1-for-25 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $6.19Mdown 96.7%
- Net income
- −$16.69M
- Diluted EPS
- −$1.29
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $40.19M | −$21.91M | −$2.93 |
| Q4 FY24 (Dec 31, 2024) | $32.75M | −$12.69M | −$0.07 |
| Q1 FY25 (Mar 31, 2025) | $98.15M | $38.01M | $3.50 |
| Q2 FY25 (Jun 30, 2025) | $17.58M | $2.39M | $0.19 |
| Q3 FY25 (Sep 30, 2025) | $3.45M | −$4.30M | −$0.32 |
| Q4 FY25 (Dec 31, 2025) | $1.60M | −$3.41M | −$0.36 |
| Q1 FY26 (Mar 31, 2026) | $516.00K | −$4.15M | −$0.29 |
| Q2 FY26 (Jun 30, 2026) | $630.00K | −$4.83M | −$0.32 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $20.34M | −$340.14M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $63.57M | −$228.30M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $8.57M | −$276.13M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $128.94M | −$85.40M | −$11.41 |
| FY25 (Dec 31, 2025) | $120.77M | $32.69M | $2.57 |
Margins
- Gross 91.4%
- Operating −229.7%
- Net −269.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$21.30MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$21.90MLast 12 months
- Capital spending$599.00KLast 12 months
- −343.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $8.79MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $9.87MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$50.32MAs of Jun 30, 2026
- Net debt$40.45MAs of Jun 30, 2026
- 1.98As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✗Operating cash flow exceeded net income: not passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −73.0%Last 12 months
Over the last 12 months, Atara Biotherapeutics’s net loss was 73.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Atara Biotherapeutics Inc
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ATRA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ATRA stock FAQ
What is ATRA stock’s price today?
Atara Biotherapeutics (ATRA) traded at $9.18 at the close on , down $0.47 (4.87%) from the previous close of $9.65. Over the past 52 weeks it has traded between $3.92 and $19.15.
If you invested $1,000 in ATRA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ATRA on would be worth about $23 at the close on , a total return of −97.7%. The same $1,000 would be worth $24 if invested five years ago and $602 if invested one year ago. Past performance doesn’t predict future returns.
What is ATRA’s P/E ratio?
ATRA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.29).
How much revenue does Atara Biotherapeutics make?
Atara Biotherapeutics reported $6.2 million of revenue over the four quarters to , down 96.7% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $630.0 thousand, down 96.4% from a year earlier.
Is Atara Biotherapeutics profitable?
Not over the four quarters to . Atara Biotherapeutics reported a net loss of $16.7 million across those four quarters on $6.2 million of revenue.
What are ATRA’s earnings per share?
ATRA’s diluted earnings per share were −$1.29 over the four quarters to , compared with $0.69 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.32 per share, against $0.19 a year earlier (how EPS works).
Does ATRA pay a dividend?
Atara Biotherapeutics hasn’t paid a dividend in the last twelve months.
What is ATRA’s 52-week high and low?
Over the past 52 weeks ATRA has traded as low as $3.92 and as high as $19.15. At $9.18 at the close on , it is 52.1% below that high and 134.2% above the low.
What is ATRA’s all-time high?
ATRA’s highest closing price was $1,600.50 on , adjusted for stock splits. At $9.18 at the close on , it is 99.4% below that record.
Has ATRA stock ever split?
Yes, once: 1-for-25 on .
How has ATRA stock performed?
Including dividends and measured to the close on , ATRA has returned −49.3% so far this year and −39.8% over the past year, and −97.6% over five years (−52.5% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Atara Biotherapeutics in?
Atara Biotherapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does ATRA trade on?
Atara Biotherapeutics trades on the Nasdaq under the ticker symbol ATRA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.